Overall: Publicly-funded cancer clinical trials continue to establish new standards of care and improve outcomes for cancer patients. ECOG-ACRIN (EA) has instituted an organizational matrix based on the integration of biological and imaging studies with clinical trials of novel anti-cancer therapies to conduct cutting-edge clinical research and promote scientific discovery. We have incorporated expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management centers at the Dana Farber Cancer Institute and Brown University, to propose a research plan that recognizes the importance of biomarkers to bring precisely targeted clinical trials to broad populations of cancer patients. The EA biorepositories, image databases, immunological laboratories, and associated translational science centers will bring together the correlative science studies that relate cancer biology to clinical markers of treatment effect in a data-rich environment. EA embraces the goals and spirit of the NCTN to conduct science-driven clinical trials to improve the lives of adults with cancer. EA clinical trials are implemented through an efficient operational infrastructure that enables access to cutting-edge treatments across the US from large cancer centers to community practices and assures accrual to complex trials in cancers of varying prevalence. Our science is driven by our membership, which includes the NCI-funded Cancer Centers, the Specialized Programs of Research Excellence (SPOREs), the ETCTN (Experimental Therapeutics Clinical Trials Network), the Quantitative Imaging Network (QIN), the NCTN Lead Academic Participating Sites (LAPS), and the National Community Oncology Research Programs (NCORP). As committed participants in the NCTN and in all aspects of CTEP-led cancer research, EA collaborates across the system to promote and advance the collective efforts of all of the groups. We make available the mentorship and opportunity needed to nourish the next generation of investigators. EA is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients. This model, together with developing innovation in large data analysis, will yield high quality trials that have the potential to be practice-changing, applicable to both academic and community environments, and providing imaging and other biomarkers to identify patients who benefit most.

Public Health Relevance

The primary goal of ECOG-ACRIN is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ecog-Acrin Medical Research Foundation
United States
Zip Code
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Phipps, Amanda I; Shi, Qian; Zemla, Tyler J et al. (2018) Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev 27:696-703
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59
Tarhini, Ahmad A; Lee, Sandra J; Li, Xiaoxue et al. (2018) E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-?2b in Advanced Melanoma. Clin Cancer Res :
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Khoury, Joseph D; Wang, Wei-Lien; Prieto, Victor G et al. (2018) Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res 24:521-531

Showing the most recent 10 out of 260 publications